138 related articles for article (PubMed ID: 17567830)
1. Predictors of response of US veterans to treatment for the hepatitis C virus.
Backus LI; Boothroyd DB; Phillips BR; Mole LA
Hepatology; 2007 Jul; 46(1):37-47. PubMed ID: 17567830
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
4. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
6. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
[TBL] [Abstract][Full Text] [Related]
7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C--treatment of untreated (naive) patients].
Duvnjak M; Pavić T; Tomasić V; Lerotić I; Virović L
Acta Med Croatica; 2005; 59(5):453-61. PubMed ID: 16381243
[TBL] [Abstract][Full Text] [Related]
9. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
10. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center experience.
Maor Y; Schapiro JM; Bashari D; Lurie Y; Safadi R; Segol O; Paritsky M; Rachlis Z; Avidan B; Bar-Meir S; Martinowitz U
Haemophilia; 2008 Mar; 14(2):336-42. PubMed ID: 18205802
[TBL] [Abstract][Full Text] [Related]
12. Persistence with hepatitis C therapy in the Department of Veterans Affairs.
Iqbal SU; Cunningham F; Lee A; Miller DR; Li NC; Cheung R; Kazis L
J Clin Pharm Ther; 2008 Jun; 33(3):251-61. PubMed ID: 18452412
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of treatment of patients infected with hepatitis C virus.
Qureshi S; Qazi MH; Aziz MT
Pak J Pharm Sci; 2018 Mar; 31(2):365-369. PubMed ID: 29618422
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus.
Backus LI; Boothroyd DB; Phillips BR; Mole LA
J Viral Hepat; 2006 Dec; 13(12):799-810. PubMed ID: 17109679
[TBL] [Abstract][Full Text] [Related]
15. Gaps in the achievement of effectiveness of HCV treatment in national VA practice.
Kramer JR; Kanwal F; Richardson P; Mei M; El-Serag HB
J Hepatol; 2012 Feb; 56(2):320-5. PubMed ID: 21756855
[TBL] [Abstract][Full Text] [Related]
16. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
Mangin EF; Jones WN
Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
[No Abstract] [Full Text] [Related]
17. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
Riley TR
Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
[No Abstract] [Full Text] [Related]
18. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres.
Jensen DM; Cotler SJ; Lam H; Harb G; Shillington A
Aliment Pharmacol Ther; 2004 Jan; 19(1):69-77. PubMed ID: 14687168
[TBL] [Abstract][Full Text] [Related]
19. Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.
Taura N; Ichikawa T; Miyaaki H; Kadokawa Y; Tsutsumi T; Tsuruta S; Kato Y; Inoue O; Kinoshita N; Ohba K; Kato H; Ohata K; Masuda J; Hamasaki K; Yatsuhashi H; Nakao K
Gastroenterol Res Pract; 2012; 2012():317580. PubMed ID: 23193392
[TBL] [Abstract][Full Text] [Related]
20. Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009.
Gundlapalli AV; Nelson RE; Haroldsen C; Carter ME; LaFleur J
PLoS One; 2015; 10(7):e0132056. PubMed ID: 26167690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
